NR-55409来自SARS相关冠状病毒2的刺突糖蛋白受体结合域(RBD),带有C末端组氨酸标签的V483A变体,来自HEK293细胞(蛋白质）的重组
产品图片
货号/SKU
NR-55409
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-55409?? Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, V483A Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, V483A Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells|-20°C or colder|ACROBiosystemsAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, V483A Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells, NR-55409.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
A recombinant form of the spike (S) glycoprotein receptor binding domain (RBD) from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), V483A variant was produced by transient transfection in human embryonic kidney HEK293 cells and purified by affinity chromatography. NR-55409 lacks the signal sequence, contains 223 residues of the SARS-CoV-2 S glycoprotein (amino acid residues R319 to F541) and features a C-terminal poly-histidine tag. NR-55409 is a variant of SARS-CoV-2 which contains the V483A mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55409 has a theoretical molecular weight of 27,000 daltons. The crystal structure for the wild-type S glycoprotein from SARS-CoV-2 has been solved at 2.8 ? resolution (PDB: 6VXX).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The V483A mutation removes an S glycoprotein glycosylation site, and SARS-CoV-2 variants with this mutation show resistance to some neutralizing antibodies.
The biological activity of NR-55409 was measured by its binding ability in a functional ELISA, in which immobilized human ACE2 protein (Fc tag) (ACROBiosystems AC2-H5257) at 5 ?g per mL (100 ?L per well) can bind NR-55409; the linear range is 2 to 50 ng per mL. Immobilized Anti-SARS-CoV-2 neutralizing antibody (ACROBiosystems SAD-S35) at 1 ?g per mL (100 ?L per well) can bind NR-55409; the linear range is 2 to 16 ng per mL. The biological activity of NR-55409 was also measured by its binding ability using biosensor analysis, in which loaded ACROBiosystems AC2-H5257 can bind NR-55409; the affinity constant is 4.13 nM by Biocore T200 and 6.15 nM by ForteBio Octet Red96e. In addition, loaded ACROBiosystems SAD-S35 can bind NR-55409; affinity constant is 4.57 nM by ForteBio Octet Red96e.
Each vial contains approximately 100 ?g of purified recombinant protein lyophilized in phosphate-buffered saline, pH 7.4 and 10% trehalose.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
A recombinant form of the spike (S) glycoprotein receptor binding domain (RBD) from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), V483A variant was produced by transient transfection in human embryonic kidney HEK293 cells and purified by affinity chromatography. NR-55409 lacks the signal sequence, contains 223 residues of the SARS-CoV-2 S glycoprotein (amino acid residues R319 to F541) and features a C-terminal poly-histidine tag. NR-55409 is a variant of SARS-CoV-2 which contains the V483A mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55409 has a theoretical molecular weight of 27,000 daltons. The crystal structure for the wild-type S glycoprotein from SARS-CoV-2 has been solved at 2.8 ? resolution (PDB: 6VXX).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The V483A mutation removes an S glycoprotein glycosylation site, and SARS-CoV-2 variants with this mutation show resistance to some neutralizing antibodies.
The biological activity of NR-55409 was measured by its binding ability in a functional ELISA, in which immobilized human ACE2 protein (Fc tag) (ACROBiosystems AC2-H5257) at 5 ?g per mL (100 ?L per well) can bind NR-55409; the linear range is 2 to 50 ng per mL. Immobilized Anti-SARS-CoV-2 neutralizing antibody (ACROBiosystems SAD-S35) at 1 ?g per mL (100 ?L per well) can bind NR-55409; the linear range is 2 to 16 ng per mL. The biological activity of NR-55409 was also measured by its binding ability using biosensor analysis, in which loaded ACROBiosystems AC2-H5257 can bind NR-55409; the affinity constant is 4.13 nM by Biocore T200 and 6.15 nM by ForteBio Octet Red96e. In addition, loaded ACROBiosystems SAD-S35 can bind NR-55409; affinity constant is 4.57 nM by ForteBio Octet Red96e.
Each vial contains approximately 100 ?g of purified recombinant protein lyophilized in phosphate-buffered saline, pH 7.4 and 10% trehalose.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
来自严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2）的峰值形式的穗糖蛋白受体结合结构域（RBD），通过瞬态转染在人胚胎肾HEK293细胞中产生V483A变体，并通过亲和力纯化色谱法. NR-55409.
缺乏信号序列，含有223个残基的SARS-COV-2S糖蛋白（氨基酸残基R319至F541），并具有C末端多组氨酸标签. NR-55409是SARS-COV-2的变体，其含有SARS-COV-2参考序列（Genpept：）. NR-55409具有27,000道尔顿的理论分子量.来自SARS-COV-2的野生型糖蛋白的晶体结构已经解决了2.8埃分辨率（PDB： 6VXX ）.
S糖蛋白介导与宿主血管紧张素转化酶2（ACE2）的病毒结合.该蛋白质形成三聚体，并且当与宿主受体结合时，允许融合病毒和细胞膜. V483A突变除去S糖蛋白糖基化位点，SARS-COV-2具有这种突变的变体显示出对一些中和抗体的抵抗力.
通过其功能ELISA的结合能力测量NR-55409的生物活性，其中固定的人ACE2蛋白（FC标签）（Acrobiosystems AC2-H5257）以5μg/ mL（每孔100μl）可以结合NR-55409 ;线性范围为每mL 2至50 ng.固定化抗SARS-COV-2中和
抗体（肌肉系统SAD-S35）在每毫升1μg（每孔100μl）中，可以结合NR-55409;线性范围为每mL 2至16 ng.通过使用生物传感器分析的结合能力，也通过其结合能力来测量NR-55409的生物活性，其中加载的辅助系统AC2-H5257可以结合NR-55409;亲和力常数由Biocore T200和6.15 NM由Fortebio八位赛Red96e进行4.13nm.此外，加载的Acrobiosystems SAD-S35可以绑定NR-55409; Fortebio Octet Red96e的亲和常数是4.57nm.
每个小瓶在磷酸盐缓冲盐水，pH 7.4和10％海藻糖中含有大约100μg纯化的重组蛋白.
vipr （病毒病原体资源）提供了附加信息和工具.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2021-12-21
2024-09-22
2022-04-01
2024-10-20
2021-12-21
2022-03-31
2024-05-19
2022-04-01
2021-12-13
2024-06-25
2022-04-01